World Lung Cancer Day
Help raise awareness and support research into lung cancer, so we can prevent, treat, and eventually cure one of the most common and deadly cancers.
Position your health/pharma brand or non-profit as a partner in lung cancer prevention and research funding during August awareness month.
- Share smoking cessation resources and success stories to drive engagement with health-conscious audiences
- Highlight corporate donations to lung cancer research or patient support programs
- Create educational content on preventable risk factors (air quality, occupational hazards, nutrition)
- Partner with healthcare providers to promote screening and early detection messaging
Lung cancer was a rare disease in early 20th century but its incidence has gradually increased with increased smoking and it has become the most common type of cancer in the world.
The lung cancers accounts for 12.8% of cancer cases and 17.8% of mortalities of cancer worldwide. Lung cancer is a preventable disease.
The factors that play a role in cancer development include tobacco products, industrial products (uranium, radiation, asbestos) air pollution, and nutritional deficiencies. Recent studies have demonstrated that the critical factor increasing the risk of lung cancer is the long-term respiration of carcinogenic materials.
Epidemiologic case-control studies by 1950s proved that smoking was strongly correlated with lung cancer. The first findings that smoking was a cause of lung cancer were published in 1962.
Smoking is responsible for developing lung cancer by 94%. The risk of lung cancer is 24-36 times higher in smokers than in non-smokers.
The risk is 3.5% in passive smoking. Age to start smoking, period of smoking, number of cigarettes smoked, and type of tobacco and cigarette have influence on the risk of developing lung cancer.
The IASLC World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
More than 7,000 delegates come from more than 100 countries to discuss the latest developments in thoracic malignancy research.
Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients.